Drugs / Adacel
Adacel
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01689324 | Sep → Nov 2012 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04142983 | Feb 2020 → Nov 2021 | tetanus | GCAM Inc. | Completed | No outcome recorded |
| Phase 36 trials · 1 met primary | ||||||
| Phase 3 | NCT01993173 | Nov 2013 → Feb 2014 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01040052 | Dec 2009 → Feb 2010 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00988884 | Oct 2009 → Feb 2011 | human papilloma virus infection | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3 | NCT00346073 | Jul 2006 → Mar 2007 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00325130 | Apr 2006 → Apr 2007 | diphtheria, meningitis, neoplasm, pertussis +1 | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00258908 | Nov 2005 → Aug 2006 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 49 trials · 1 met primary | ||||||
| Phase 4 | NCT06803524 | May → Jun 2025 | pertussis | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT04543669 | Jul → Sep 2017 | pertussis | Dalhousie University | Completed | No outcome recorded |
| Phase 4 | NCT01711645 | Oct 2012 → Aug 2015 | diphtheria, pertussis, tetanus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT01439165 | Nov 2011 → Dec 2015 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01311557 | Mar → Nov 2011 | diphtheria, pertussis, tetanus | Sanofi | Completed | Met primary |
| Phase 4 | NCT01137435 | Jun 2010 → Mar 2016 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT00457249 | Mar 2007 → Sep 2008 | diphtheria, pertussis, tetanus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00336115 | Jul 2006 → May 2008 | pertussis | Queen Elizabeth II Health Sciences Centre | Unknown | No outcome recorded |
| Phase 4 | NCT00319553 | May 2006 → Oct 2008 | diphtheria, pertussis, tetanus | Sanofi | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1/2 | NCT02587520 Comparator | Oct 2015 → Feb 2017 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT02199691 Comparator | Jul 2014 → Oct 2015 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT01642589 Comparator | Jul 2012 → Jan 2013 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00489970 Comparator | Jun 2007 → Sep 2011 | diphtheria, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT05264662 Comparator | Mar 2022 → Mar 2025 | — | Farzanah Laher | Completed | No outcome recorded |
| Phase 4 | NCT00712959 Comparator | Jun 2008 → Sep 2009 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-05-30 | BioNet-Asia Co., Ltd. | BioNet and Bio Farma Sign Strategic MoU to Expand TdaP Vaccine Access in ASEAN bionet-asia.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adacel | “This is a single site, prospective study involving only one intervention, receipt of a single 0.5 mL intramuscular (IM) dose of Adacel (Tetanus toxoid, reduced diphtheria...” NCT01711645 ↗23“Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Adacel™ vaccine administered intramuscularly in the deltoid region of the...” NCT00346073 ↗ “Participants will receive Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap - Adacel®)” NCT01642589 ↗ “Participants randomized to receive a repeat dose of Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine (Adacel®)” NCT01439165 ↗ “Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan” NCT00258908 ↗ “Healthy participants aged 10-18 years received Adacel®.” NCT02587520 ↗ |
| Known as | Adacel (Tdap) | “Adacel® (Tdap)” NCT02199691 ↗ |
| Known as | Tdap vaccine | “tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (ADACEL®, Tdap vaccine)” NCT01689324 ↗ |
| Known as | Tdap5 | “This study was conducted to determine whether Tdap5 (Adacel), which is licensed for use in children beginning at 11 years of age, is as safe and immunogenic in 10-year-olds as...” PMID 25230939 ↗ Sep 2014 |
| Modality | Vaccine | “ADACEL™ (TdcP Vaccine)” NCT00258908 ↗ |
| Route | Intramuscular | “Intramuscular” NCT00258908 ↗ |